glp-1 agonists reduce inflammation Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation: Cell Metabolism A Comprehensive Review of the

Theyre serious medications with strict usage requirements that are intended for chronic weight management." Researchers have also raised concerns that GLP-1 receptor agonists could be linked to more serious illnesses

4,6 A key issue in the physiology of type 2 diabetes (T2DM) is the reduced incretin effect, which mainly results from decreased activity of the primary incretin hormones, GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic peptide)

Author Contributions All authors have reviewed the final manuscript prior to submission

So I called up a co-author of the study, the Washington University physician-scientist Ziyad Al-Aly

For detailed comparison of these medication options, see our Zepbound vs Wegovy guide

supply shortages are common due to high demand